NEXGEL, INC.
NEXGEL manufactures high-water-content, electron beam cross-linked aqueous polymer hydrogels for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It supplies custom gels as a contract manufacturer to third parties, which incorporate them into their products. NEXGEL also sells branded consumer products, including MedaGel, Kenkoderm and Silly George, through e-commerce, retail partnerships and specialized medical office channels. Its custom and white-label business provides finished products for customers to brand and resell; customers pay a development fee for custom products. The company is developing medical devices, including NEXDrape surgical drapes and NEXDerm adhesive tape, and is pursuing potential licensing and partnering arrangements to bring devices to market. NEXGEL operates a combined corporate office and manufacturing facility in Langhorne, Pennsylvania, and has a 50% interest in a joint venture in Granbury, Texas.
No SEC Form 4 filings for $NXGL in the last 30 days.
See all $NXGL insider activity →NEXGEL, INC. (NXGL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NEXGEL Announces Noteholder Participation in Strategic Recapitalization and Approximately $1.2 Million in New Capital Funding Approximately 95% of Outstanding Convertible Note Principal Committed to Conversion, Subject to Completion of a Strategic Merger Sequence Lif
NEXGEL, Inc. (NASDAQ: NXGL) announced that 95% of its convertible noteholders, representing $14.125 million, agreed to convert notes into common stock, contingent on a strategic merger and other conditions. The company has secured $1.2 million in commitments, with Sequence LifeScience contributing 61%. NXGL is pursuing cost savings and a potential merger with Fountainhead LifeSciences, with a deadline of March 31, 2027.
NexGel (NXGL) plans to release Q3'26 earnings on November 17. Analysts expect revenue of 4.19M USD and an EPS of (4.80) USD. The announcement is scheduled for 7:00 AM ET (12:00 PM UTC).
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning NXGL (NEXGEL, INC.). Coverage has skewed bullish: 2 bullish, 2 neutral, and 1 bearish.
Recent NXGL coverage spans corporate actions, earnings and financial news.
Conversion reduces debt and adds liquidity, likely supporting share price.
High likelihood of balance-sheet de-risking via debt conversion, but conversion timing hinges on whether the related-party merger closes by March 31, 2027.
Estimate suggests modest revenue; market may price in a small upside or downside depending on actual results.
Regaining compliance removes delisting risk and may support the stock price.
Reverse split starts trading on a split-adjusted basis, which can change liquidity, per-share price optics, and compliance optics.
AlphAI scores every news story that mentions NXGL with an AI model for sentiment and relevance, and aggregates insider trades from NEXGEL, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
NEXGEL, INC. (NXGL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NEXGEL Announces Noteholder Participation in Strategic Recapitalization and Approximately $1.2 Million in New Capital Funding Approximately 95% of Outstanding Convertible Note Principal Committed to Conversion, Subject to Completion of a Strategic Merger Sequence Lif
NEXGEL, Inc. (NASDAQ: NXGL) announced that 95% of its convertible noteholders, representing $14.125 million, agreed to convert notes into common stock, contingent on a strategic merger and other conditions. The company has secured $1.2 million in commitments, with Sequence LifeScience contributing 61%. NXGL is pursuing cost savings and a potential merger with Fountainhead LifeSciences, with a deadline of March 31, 2027.
NexGel (NXGL) plans to release Q3'26 earnings on November 17. Analysts expect revenue of 4.19M USD and an EPS of (4.80) USD. The announcement is scheduled for 7:00 AM ET (12:00 PM UTC).
NEXGEL, Inc. (NXGL) regained compliance with Nasdaq's minimum bid price requirement, avoiding delisting. The company's stock will continue trading on the Nasdaq Capital Market. NEXGEL operates in medical technology and hydrogel products. The announcement follows a notification in April 2026 of non-compliance, which was resolved by October 2026.
NEXGEL, Inc. (NXGL) announced a 1-for-20 reverse stock split, effective October 12, 2026. The split reduces outstanding shares from 9,747,663 to approximately 487,384, aiming to meet Nasdaq's $1.00 minimum bid price requirement. Trading continues under the symbol 'NXGL' on the Nasdaq Capital Market.
NEXGEL, Inc. (NXGL) affiliate Adam R. Levy proposed selling 227,956 shares, valued at $41,214, and 21,500 shares, valued at $3,488.98, with sales expected around September 2026. Levy acquired shares via open-market purchases and stock grants from 2019 to 2025.
NEXGEL, INC. (NXGL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 23, 2026, NexGel, Inc. (the “Company” ) held its 2026 Special Meeting of Stockholders (the “Special Meeting” ). At the Special Meeting, there were 6,200,043 shares of common stock represented in person o
NEXGEL, INC. (NXGL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE LANGHORNE, Pa. – August 20, 2026 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”) today announced a series of leadership, governance and strategic initiatives designed to strengthen ope
NEXGEL (NXGL) reported Q2 2026 revenue of $3.69M, up from $2.88M a year earlier, citing Celularity transaction growth and BioNX Surgical integration. The quarter showed a net loss of $2.87M, attributed to integration costs, intangible amortization, transaction expenses, and a SilverSeal inventory recall. Shares trade around $0.39, down 30% YTD.
NEXGEL, INC. (NXGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEXGEL Reports Second Quarter 2026 Financial Results LANGHORNE, Pa. – August 17, 2026 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content
